Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.

OBJECTIVES To evaluate the rate, effect, and predictive factors of a complete pathologic response (cPR) in patients with hepatocellular carcinoma (HCC) undergoing locoregional therapy (LRT) before liver transplantation (LT). BACKGROUND Eligible patients with HCC receive equal model for end-stage liver disease prioritization, despite variable risks of tumor progression, waitlist dropout, and posttransplant recurrence. Pretransplant LRT mitigates these risks by inducing tumor necrosis. METHODS Comparisons were made among HCC recipients with cPR (n = 126) and without cPR (n = 375) receiving pre-LT LRT (1994-2013). Multivariable predictors of cPR were identified. RESULTS Of 501 patients, 272, 148, and 81 received 1, 2, and 3 or more LRT treatments. The overall, recurrence-free, and disease-specific survival at 1-, 3-, and 5 years was 86%, 71%, 63%; 84%, 67%, 60%; and 97%, 90%, 87%. Compared with recipients without cPR, cPR patients had significantly lower laboratory model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were more likely to have 1 lesion, tumors within Milan/University of California, San Francisco (UCSF) criteria, LRT that included ablation, and a favorable tumor response to LRT; and had superior 1-, 3-, and 5-year recurrence-free survival (92%, 79%, and 73% vs 81%, 63%, and 56%; P = 0.006) and disease-specific survival (100%, 100%, and 99% vs 96%, 89%, and 86%; P < 0.001) with only 1 cancer-specific death and fewer recurrences (2.4% vs 15.2%; P < 0.001). Multivariate predictors of cPR included a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumor diameter (C-statistic 0.75). CONCLUSIONS Achieving cPR in patients with HCC receiving LRT strongly predicts tumor-free survival. Factors predicting cPR are identified, allowing for differential prioritization of HCC recipients based on their variable risks of post-LT recurrence. Improving LRT strategies to maximize cPR would enhance posttransplant cancer outcomes.

[1]  A. Israni,et al.  Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States , 2015, Hepatology.

[2]  Ali Zarrinpar,et al.  A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. , 2015, Journal of the American College of Surgeons.

[3]  W. Kim,et al.  Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  J. Emond,et al.  Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment , 2014, Hepatology.

[5]  J. Roberts,et al.  Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  R. Hirose,et al.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  M. Pompili,et al.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. , 2013, World journal of gastroenterology.

[8]  Massimo Rossi,et al.  Alpha‐fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  Johnny C. Hong,et al.  The Evolution of Liver Transplantation During 3 Decades: Analysis of 5347 Consecutive Liver Transplants at a Single Center , 2013, Annals of surgery.

[10]  A. Burroughs,et al.  Transarterial embolization as neo‐adjuvant therapy pretransplantation in patients with hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[11]  E. Vittinghoff,et al.  Offer patterns of nationally placed livers by donation service area , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  R. Wiesner,et al.  Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease , 2013, Transplantation.

[13]  Peter G. Stock,et al.  OPTN/SRTR 2011 Annual Data Report: Liver , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  M. Reiser,et al.  Multimodality Treatment for Early-Stage Hepatocellular Carcinoma: A Bridging Therapy for Liver Transplantation , 2012, Digestion.

[15]  S. Kwan,et al.  Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: A radiological‐pathological correlation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  F. Piscaglia,et al.  Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  B. Caffo,et al.  MELD Exceptions and Rates of Waiting List Outcomes , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  P. Majno,et al.  Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  P. Morel,et al.  The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. , 2011, Journal of hepatology.

[20]  A. Cucchetti,et al.  Can the Dropout Risk of Candidates with Hepatocellular Carcinoma Predict Survival after Liver Transplantation? , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  M. Carpenzano,et al.  Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas , 2011, Hepatology.

[22]  A. Venook,et al.  Hepatocellular carcinoma: Ablate and wait versus rapid transplantation , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  R. Freeman,et al.  Hepatocellular Carcinoma Patients Are Advantaged in the Current Liver Transplant Allocation System , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  A. Frigo,et al.  Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation , 2010, Annals of Surgical Oncology.

[25]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[26]  W. Chapman,et al.  Outcomes of Neoadjuvant Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Before Liver Transplantation , 2008, Annals of surgery.

[27]  Ryutaro Hirose,et al.  Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis , 2008, Hepatology.

[28]  G. Ioannou,et al.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. , 2008, Gastroenterology.

[29]  T. Serrano,et al.  Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. , 2008, AJR. American journal of roentgenology.

[30]  R. Merion,et al.  Liver and Intestine Transplantation in the United States, 1997–2006 , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  W. Jaschke,et al.  Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  T. Pfammatter,et al.  Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence‐Based Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  G. Otto,et al.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  M. Pompili,et al.  Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  Sammy Saab,et al.  Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation , 2005, Hepatology.

[36]  L. Mariani,et al.  Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study , 2004, Annals of surgery.

[37]  G. Klintmalm,et al.  Liver and intestine transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  R. Wiesner,et al.  Liver and intestine transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[40]  H. Bismuth,et al.  Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. , 1997, Annals of surgery.

[41]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[42]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[43]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.